VU0134992 is a selective Kir4.1 potassium channel pore blocker.

Tolbutamide (also known as HLS 831; trade names: Artosin, Diabetol, Orinase), a sulfonylurea analog, is a potent and selective inhibitor of potassium channel used as an oral blood-glucose-lowering/hypoglycemic medication.

Clofilium tosylate, the tosylate salt of clofilium, is a novel and potent potassium/K+ channel blocker with the potential to be used as a cardiac depressant and anti-arrhythmic agent.

SPS-4251 [PAP-1; SPS4251; 5-(4-Phenoxybutoxy)psoralen] is a novel and potent KCNA3 channel blocker (inhibitor of Kv1.3, voltage-gated K+ channel) with the potential to be used in treatment of multiple sclerosis.

Glimepiride (HOE-490; HOE490; Amaryl; Glimepiridum; Amarel; Glimepirida; Roname), a third generation and medium-to-long acting sulfonylurea compound, is a potent Kir6.2/SUR inhibitor with potential antidiabetic activity.

ML402 (ML-402) is a potent and selective activator of TREK-1/-2 and an agonist for OPRM1-OPRD1 (OPRM1: opioid receptor mu 1; OPRD1: delta opioid receptor) heterdimerization.

TRAM-34 (TRAM34; TRAM 34 Triarylmethane-34) is an inhibitor of Ca2+-activated K+ channel (IKCa1, KCa3.1) with important biological activity.

ML365 is a potent, novel and selective small molecule inhibitor of the TASK1(KCNK3, a two-pore domain potassium channel).

Nigericin sodium, the sodium salt of nigericin which is an antibiotic isolated from Streptomyces hygroscopicus, is a cationic ionophore that inhibits Golgi function and suppresses growth of gram positive bacteria.

Amifampridine (trade name: Firdapse; pyridine-3,4-diamine, 3,4-diaminopyridine, 3,4-DAP) is an FDA approved drug used predominantly in the treatment of a number of rare muscle diseases such as Lambert-Eaton myasthenic syndrome (LEMS) in adults.